| Name | Title | Contact Details |
|---|---|---|
Donna Loomis |
Senior Vice President and General Counsel | Profile |
Trent Pepper |
General Counsel and Senior Vice President of Legal Services | Profile |
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Versicolor Technologies has developed the world`s first cosmetic and therapeutic technology platform to address pigmentation and skin aging, by leveraging small molecule compounds produced naturally in the human microbiome.
Spectranetics is dedicated to managing every lead and eradicating restenosis and amputation. We do this by helping physicians, patients, and hospitals maximize cardiovascular health. Our company is committed to inventing, selling, and supporting technology that enables success during the most challenging minimally invasive cardiovascular procedures. We provide expert physician training, including the only lead removal simulator in the industry, as well as extensive patient and physician education. The Company’s Lead Management (LM) division is dedicated to helping physicians safely manage every lead. We provide the expert tools, training and ongoing support – including the only available lead extraction simulator – that allow physicians precision, control and versatility while extracting leads, so they can focus more on the patient’s overall status while generating positive outcomes. The Vascular Intervention (VI) division is dedicated to helping physicians address the challenges of peripheral and coronary artery disease. We provide expert tools, training, ongoing support, and patient education so that you can help eradicate restenosis and amputation
CRI Worldwide is a Clementon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Non-profit Mary Ann Morse Healthcare Corp. provides continuum of affordable, quality senior living and healthcare services in Metro West.